Compare Biogen Inc (BIIB) vs EOG Resources Inc (EOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs EOG Resources Inc — how do they compare? Biogen Inc trades at $204.1 (market cap $30.60B), while EOG Resources Inc trades at $144 (market cap $74.60B). The key difference: EOG Resources Inc is far larger — about 2.4× Biogen Inc's market cap, and EOG Resources Inc pays a 2.87% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | EOG | |
|---|---|---|
Market Cap | $30.60B | $74.60B |
Sector | Health | Energy |
52-Week High | $216.63 | $149.89 |
52-Week Low | $128.00 | $101.78 |
Enterprise Value | $37.67B | $77.94B |
Dividend Yield | — | 2.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $207.94, up 0.8% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $234.47. The company has beaten earnings estimates for three consecutive quarters, including Q2 2026 EPS of $3.60 versus $2.94 expected, and recently completed the acquisition of RayThera Inc. to bolster its immunology pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%.
The outlook is positive, driven by strong execution and growth from newer drugs like Leqembi, though risks include pressure on legacy multiple sclerosis sales and a high P/E ratio of 36.93. The stock offers potential upside to the analyst target but faces earnings volatility and integration risks from recent acquisitions.
EOG Resources trades at $134.74, down 1.07% with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $5.07, beating estimates, with revenue growth driven by higher oil prices and production. Valuation metrics remain attractive with P/E of 10.49 and EV/EBITDA of 5.32, while maintaining robust profitability with 25.81% net margin and 22.51% ROE.
EOG presents a compelling value opportunity with strong earnings momentum and shareholder returns through dividends. However, negative cash flow trends and energy price volatility pose near-term risks. Analyst consensus remains bullish with $162.11 price target, representing 20% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About EOG Resources Inc
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →
